Nitec Pharma Ag, a Swiss company that specialises in treating chronic inflammation and pain-related diseases, has appointed Hans Fünfschilling as non-executive chairman. He replaces Hubertus Ludwig, who will remain on the board and who was chairman when the company was spun out from Merck KGaA in 2004.
Until recently, Dr Fünfschilling was the sole representative of the Canton of Baselland on the Ständerat, the Swiss Council of States. He also has served in senior executive positions at Roche for 19 years.
Source:
Nitec Pharma press release, 4 December 2007
Copyright 2007 Evernow Publishing Ltd